hypericin has been researched along with Cancer of Nasopharynx in 18 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to explore the combined effects of gene therapy and hypericin (Hy) on tumor cells, hypoxia-inducible factor 1 alpha (HIF-1α) small interfering ribonucleic acid (siRNA) was transfected into the hypoxic human nasopharyngeal carcinoma (CNE2) cells using Hy-encapsulated nanocomplexes (Hy-HPP NPs) as a carrier which would achieve dual targeting to the tumor necrosis area." | 3.83 | Co-delivery of siRNA and hypericin into cancer cells by hyaluronic acid modified PLGA-PEI nanoparticles. ( Li, Y; Ouahab, A; Shen, Y; Wang, B; Zhang, J, 2016) |
| "Hypericin is known to generate a high yield of singlet oxygen and other reactive oxygen species that are associated with photo-oxidative cellular damage." | 2.43 | Hypericin lights up the way for the potential treatment of nasopharyngeal cancer by photodynamic therapy. ( Bay, BH; Du, HY; Olivo, M, 2006) |
| "Since there are no reports of IL-6 in nasopharyngeal cancer (NPC) cells following PDT, we evaluated IL-6 expression in two different NPC tumors after hypericin mediated PDT." | 1.33 | Hypericin-mediated photodynamic therapy elicits differential interleukin-6 response in nasopharyngeal cancer. ( Bay, BH; Du, H; Mahendran, R; Olivo, M, 2006) |
| " However, the tumors administered with a initial dose of CX at 24-h post-PDT had no tumor control." | 1.33 | Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma. ( Olivo, M; Soo, KC; Yee, KK, 2005) |
| "Hypericin appears to be an effective photosensitizer for the treatment of NPC." | 1.32 | Biodistribution and photodynamic therapy with hypericin in a human NPC murine tumor model. ( Bay, BH; Du, HY; Olivo, M, 2003) |
| "Hypericin is a photosensitizer, which is known to generate reactive oxygen species upon activation with light." | 1.32 | Photoactivation of hypericin down-regulates glutathione S-transferase activity in nasopharyngeal cancer cells. ( Bay, BH; Du, HY; Olivo, M; Tan, BK, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (88.89) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 3 |
| Zhang, J | 2 |
| Wang, B | 1 |
| Shen, Y | 1 |
| Ouahab, A | 1 |
| Olivo, M | 16 |
| Du, HY | 7 |
| Bay, BH | 10 |
| Wang, X | 1 |
| Guo, Y | 1 |
| Yang, S | 1 |
| Wang, C | 1 |
| Fu, X | 1 |
| Wang, J | 1 |
| Mao, Y | 1 |
| Ali, SM | 2 |
| Tan, BK | 2 |
| Du, H | 3 |
| Mahendran, R | 4 |
| Zhou, Q | 1 |
| Lye, KY | 1 |
| Moore, S | 1 |
| Sharma, A | 1 |
| Chowbay, B | 1 |
| Thong, PS | 1 |
| Watt, F | 1 |
| Ren, MQ | 1 |
| Tan, PH | 2 |
| Soo, KC | 3 |
| Chen, YJ | 1 |
| Yip, G | 1 |
| Matsumoto, K | 1 |
| Tsujimoto, M | 1 |
| Yee, KK | 2 |
| Yip, GW | 1 |
| Huang, Q | 1 |
| Shen, HM | 1 |
| Ong, CN | 1 |
| Bhuvaneswari, R | 1 |
| Gan, YY | 1 |
| Chee, SK | 1 |
| Yuen, GY | 1 |
1 review available for hypericin and Cancer of Nasopharynx
| Article | Year |
|---|---|
Hypericin lights up the way for the potential treatment of nasopharyngeal cancer by photodynamic therapy.
Topics: Animals; Anthracenes; Cytokines; Humans; Lipid Peroxidation; Matrix Metalloproteinase 1; Nasopharyng | 2006 |
1 trial available for hypericin and Cancer of Nasopharynx
| Article | Year |
|---|---|
Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Anthracenes; Antineoplastic Agents; Chemotherapy, | 2005 |
16 other studies available for hypericin and Cancer of Nasopharynx
| Article | Year |
|---|---|
Co-delivery of siRNA and hypericin into cancer cells by hyaluronic acid modified PLGA-PEI nanoparticles.
Topics: Anthracenes; Carcinoma; Cell Line, Tumor; Humans; Hyaluronic Acid; Hypoxia-Inducible Factor 1, alpha | 2016 |
Cellular and molecular mechanisms of photodynamic hypericin therapy for nasopharyngeal carcinoma cells.
Topics: Anthracenes; Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Repair; DNA Repli | 2010 |
Bio-distribution and subcellular localization of Hypericin and its role in PDT induced apoptosis in cancer cells.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Colonic Neoplasms; Cytochrome c Group; Humans; Intrac | 2002 |
Biodistribution and photodynamic therapy with hypericin in a human NPC murine tumor model.
Topics: Animals; Anthracenes; Carcinoma, Squamous Cell; Cell Division; Humans; Kinetics; Male; Mice; Mice, N | 2003 |
Hypericin-mediated photodynamic therapy induces lipid peroxidation and necrosis in nasopharyngeal cancer.
Topics: Animals; Anthracenes; Antioxidants; Apoptosis; Cell Line, Tumor; Cytoplasm; Humans; Light; Lipid Per | 2003 |
Modulation of Matrix metalloproteinase-1 in nasopharyngeal cancer cells by photoactivation of hypericin.
Topics: Animals; Anthracenes; Antineoplastic Agents; Blotting, Western; Cell Differentiation; Cell Line, Tum | 2004 |
Photoactivation of hypericin down-regulates glutathione S-transferase activity in nasopharyngeal cancer cells.
Topics: Animals; Anthracenes; Cell Differentiation; Cell Division; Down-Regulation; Glutathione Transferase; | 2004 |
Hypericin-mediated photodynamic therapy elicits differential interleukin-6 response in nasopharyngeal cancer.
Topics: Anthracenes; Cell Line, Tumor; Humans; Interleukin-6; Nasopharyngeal Neoplasms; Perylene; Photochemo | 2006 |
Hypericin-photodynamic therapy (PDT) using an alternative treatment regime suitable for multi-fraction PDT.
Topics: Animals; Anthracenes; Apoptosis; Calcium; Immunohistochemistry; Light; Mice; Mice, Inbred BALB C; Mi | 2006 |
Expression of Y-Box binding protein-1 following hypericin-mediated photodynamic therapy in well-differentiated nasopharyngeal cancer in vivo.
Topics: Animals; Anthracenes; Antineoplastic Agents; Carcinoma; Humans; Male; Mice; Mice, Inbred BALB C; Nas | 2005 |
Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Anthracenes; Celecoxib; Cyclooxygenase 2; Drug Therapy, Combinatio | 2005 |
Differential up-regulation of metallothionein isoforms in well-differentiated nasopharyngeal cancer cells in vitro by photoactivated hypericin.
Topics: Anthracenes; Flow Cytometry; Humans; In Vitro Techniques; Metallothionein; Nasopharyngeal Neoplasms; | 2006 |
Hypericin photoactivation triggers down-regulation of matrix metalloproteinase-9 expression in well-differentiated human nasopharyngeal cancer cells.
Topics: Animals; Anthracenes; Cell Line, Tumor; Down-Regulation; Fibroblasts; Granulocyte-Macrophage Colony- | 2007 |
Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Anthracenes; Celecoxib; Gene Expression Regulation, Neoplastic; Hu | 2007 |
Hypericin and hypocrellin induced apoptosis in human mucosal carcinoma cells.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Line; Cell Membrane; Cell S | 2001 |
Endogenous expression of interleukin-8 and interleukin-10 in nasopharyngeal carcinoma cells and the effect of photodynamic therapy.
Topics: Anthracenes; Cytokines; Flow Cytometry; Humans; Interleukin-10; Interleukin-8; Nasopharyngeal Neopla | 2002 |